FORTIS Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Fortis Healthcare enters its Q4 earnings call amidst a significant capacity expansion phase, with investors focused on whether recent bed additions can drive higher occupancy and margin expansion. The print will likely center on the company's progress toward its long-term EBITDA margin targets and the integration status of its newly acquired facilities.

FORTIS Q4 Results Date and Time

The board meeting is scheduled for May 22, 2026, to consider the Q4/FY26 audited results and potential final dividend.

A virtual conference call is scheduled for May 25, 2026, at 11:00 AM IST to discuss the audited financial results.

What to expect from FORTIS's Q4 FY26 results

In its most recently reported quarter, Fortis Healthcare posted revenue of Rs. 2,265 Cr, PAT of Not stated, and an EBITDA margin of 22.3%. The company added 750 beds in 9M FY26, with management targeting a further 430+ beds on a consolidated level for FY27. While occupancy stood at 67% in Q3 FY26, management continues to focus on ramping up newer units like Noida and Greater Noida to improve operational leverage. The upcoming call will likely address the impact of recent tax demands totaling Rs. 266.16 Cr and provide updates on the ongoing litigation with Daiichi Sankyo, which has a final judgment scheduled for September 10, 2026.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against stated operational and financial milestones.

• Hospital EBITDA margin target of 25% within the next couple of years — Q3 FY26 at 21.7% — On track
• FY26 bed addition target of 900 beds — 750 beds added in 9M — Track to meet
• FY27 bed addition target of 400+ beds — Target set — On track
• Double-digit Diagnostics revenue growth — Q3 FY26 at 8.3% YoY — In progress

Strategic Expansion and Integration: Updates on facility ramp-ups and M&A integration.

• FMRI 200-bed tower operationalization timeline targeted for H1 FY27
• People Tree facility investment plan to scale from 125 beds to 300+ beds over 3-4 years
• Integration progress and initial booking contribution from Gleneagles O&M units

Operational Metric Trajectory: Focus on occupancy and specialty contribution.

• Occupancy trends at underperforming facilities including BG Road, Manesar, and Greater Noida
• Sustainability of ARPOB growth and case mix evolution driven by robotic surgeries
• Impact of new facility launches like Adayu on overall occupancy levels

Risks and Headwinds to Monitor: Management-flagged legal and operational risks.

• Resolution progress on tax demands of Rs. 149.12 Cr and Rs. 117.04 Cr received by subsidiary
• Update on NTK vs Daiichi Sankyo litigation ahead of September 10, 2026 judgment
• Legal cost reduction trajectory following corporate restructuring